SMS Lifesciences India Limited (SMSLIFE) - Total Assets
Based on the latest financial reports, SMS Lifesciences India Limited (SMSLIFE) holds total assets worth Rs3.94 Billion INR (≈ $42.60 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See SMS Lifesciences India Limited book value and equity for net asset value and shareholders' equity analysis.
SMS Lifesciences India Limited - Total Assets Trend (2016–2025)
This chart illustrates how SMS Lifesciences India Limited's total assets have evolved over time, based on quarterly financial data.
SMS Lifesciences India Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
SMS Lifesciences India Limited's total assets of Rs3.94 Billion consist of 38.6% current assets and 61.4% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs10.05 Million | 0.4% |
| Accounts Receivable | Rs687.87 Million | 17.6% |
| Inventory | Rs673.98 Million | 17.3% |
| Property, Plant & Equipment | Rs2.32 Billion | 59.5% |
| Intangible Assets | Rs515.00K | 0.0% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how SMS Lifesciences India Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SMSLIFE market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SMS Lifesciences India Limited's current assets represent 38.6% of total assets in 2025, a decrease from 53.1% in 2016.
- Cash Position: Cash and equivalents constituted 0.4% of total assets in 2025, up from 0.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is property, plant & equipment at 59.5% of total assets.
SMS Lifesciences India Limited Competitors by Total Assets
Key competitors of SMS Lifesciences India Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
SMS Lifesciences India Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.06 | 1.07 | 1.27 |
| Quick Ratio | 0.55 | 0.58 | 0.69 |
| Cash Ratio | 0.00 | 0.01 | 0.00 |
| Working Capital | Rs79.54 Million | Rs107.16 Million | Rs249.52 Million |
SMS Lifesciences India Limited - Advanced Valuation Insights
This section examines the relationship between SMS Lifesciences India Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.71 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -0.1% |
| Total Assets | Rs3.90 Billion |
| Market Capitalization | $42.13 Million USD |
Valuation Analysis
Below Book Valuation: The market values SMS Lifesciences India Limited's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: SMS Lifesciences India Limited's assets decreased by 0.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for SMS Lifesciences India Limited (2016–2025)
The table below shows the annual total assets of SMS Lifesciences India Limited from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs3.90 Billion ≈ $42.18 Million |
-0.14% |
| 2024-03-31 | Rs3.91 Billion ≈ $42.23 Million |
+15.75% |
| 2023-03-31 | Rs3.37 Billion ≈ $36.49 Million |
-5.43% |
| 2022-03-31 | Rs3.57 Billion ≈ $38.58 Million |
+18.01% |
| 2021-03-31 | Rs3.02 Billion ≈ $32.69 Million |
+19.57% |
| 2020-03-31 | Rs2.53 Billion ≈ $27.34 Million |
-6.34% |
| 2019-03-31 | Rs2.70 Billion ≈ $29.19 Million |
+52.81% |
| 2018-03-31 | Rs1.77 Billion ≈ $19.10 Million |
-0.09% |
| 2017-03-31 | Rs1.77 Billion ≈ $19.12 Million |
+2.60% |
| 2016-03-31 | Rs1.72 Billion ≈ $18.64 Million |
-- |
About SMS Lifesciences India Limited
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, a… Read more